Showing results (81-90 of 208) with videos related to

Sort By:
Pageof 21
Plos One|September 18, 2009
High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphomaSaloua Toujani, Philippe Dessen, Nathalie Ithzar, et al.
Cancers|November 13, 2021
CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 ImmunotherapyJean-Marie Michot, Severine Mouraud, Julien Adam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2016
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and LymphomasJeffrey R Infante, Philippe A Cassier, John F Gerecitano, et al.
Blood|November 2, 2006
Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trialsCéline Bossard, Karim Belhadj, Felix Reyes, et al.
Cancer Chemotherapy and Pharmacology|December 5, 2009
Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trialDelphine Rolland, Vincent Ribrag, Corinne Haioun, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2011
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective studyDidier Decaudin, Nicolas Mounier, Hervé Tilly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2013
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphomaVincent Ribrag, Jehan Dupuis, Herve Tilly, et al.
European Journal of Haematology|January 29, 2021
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapyPamela Abdayem, Nathalie Ibrahim, Yolla El Dakdouki, et al.
Cancer Medicine|April 7, 2020
Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomasKhalil Saleh, Jean-Marie Michot, Antoine Schernberg, et al.
Oncoimmunology|March 26, 2013
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylatePatricia Pautier, Clara Locher, Caroline Robert, et al.
Pageof 21